Source:http://linkedlifedata.com/resource/pubmed/id/14722233
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2004-1-14
|
pubmed:abstractText |
It remains unclear to what extent drugs targeting transcriptional repressor complexes affect global gene expression in cells derived from target and nontarget human tissues. To address this question, we used genome-wide expression analysis using microarrays to analyze the response of three tumor and one normal epithelial cell line to treatment with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine (5-aza-CdR). Notably, we found that 5-aza-CdR treatment induced a limited number of genes (mean, 0.67%; range, 0.17-1.8% of 25,940 genes screened) in each cell line tested. The majority of the gene expression changes that followed 5-aza-CdR treatment were conserved in tumor and normal cells, including genes that function in cell proliferation, differentiation, immune presentation, and cytokine signaling. In contrast, 5-aza-CdR treatment induced the expression of cancer-testis class tumor antigens only in tumor cell lines. To explain this tissue-specific response, we analyzed the mechanism of transcriptional regulation of the prototype member of this tumor antigen gene family, MAGE-1. Taken from our analysis of MAGE-1 gene regulation, we propose that 5-aza-CdR-mediated gene activation has two distinct requirements: 1) the reversal of promoter hypermethylation, and 2) the presence of transcriptional activators competent for the activation of hypomethylated target promoters. This latter requirement for gene activation by 5-aza-CdR is probably mediated by sequence-specific transcription factors and may account for the limited number of human genes induced by 5-aza-CdR treatment. This revised model for gene activation by 5-aza-CdR has important implications for the use of DNA methyltransferase inhibitors in clinical settings.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Azacitidine,
http://linkedlifedata.com/resource/pubmed/chemical/DNA Modification Methylases,
http://linkedlifedata.com/resource/pubmed/chemical/MAGEA1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Melanoma-Specific Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/decitabine
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0026-895X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
65
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
18-27
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:14722233-Antigens, Neoplasm,
pubmed-meshheading:14722233-Antimetabolites, Antineoplastic,
pubmed-meshheading:14722233-Azacitidine,
pubmed-meshheading:14722233-Cell Line, Tumor,
pubmed-meshheading:14722233-DNA Methylation,
pubmed-meshheading:14722233-DNA Modification Methylases,
pubmed-meshheading:14722233-Epithelial Cells,
pubmed-meshheading:14722233-Gene Expression Regulation,
pubmed-meshheading:14722233-Humans,
pubmed-meshheading:14722233-Melanocytes,
pubmed-meshheading:14722233-Melanoma,
pubmed-meshheading:14722233-Melanoma-Specific Antigens,
pubmed-meshheading:14722233-Multigene Family,
pubmed-meshheading:14722233-Neoplasm Proteins,
pubmed-meshheading:14722233-Transcriptional Activation
|
pubmed:year |
2004
|
pubmed:articleTitle |
Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine.
|
pubmed:affiliation |
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
|
pubmed:publicationType |
Journal Article
|